In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Horizon pays $800mm to acquire orphan drug company Raptor

Executive Summary

Horizon Pharma PLC acquired all outstanding shares of public biotech Raptor Pharmaceutical Corp. (rare disease therapeutics) for $9 apiece in cash (a 21% premium), valuing the transaction at $800mm, or over eight times Raptor's 2015 revenues of $94.2mm. Horizon will finance the purchase (expected to close in Q4 2016) with cash on hand and a planned $675mm debt financing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies